GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » EV-to-FCF

Genvec (Genvec) EV-to-FCF : -2.30 (As of May. 05, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genvec EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Genvec's Enterprise Value is $16.36 Mil. Genvec's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2017 was $-7.10 Mil. Therefore, Genvec's EV-to-FCF for today is -2.30.

The historical rank and industry rank for Genvec's EV-to-FCF or its related term are showing as below:

GNVC's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 4.57
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Genvec's stock price is $7.193. Genvec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 was $-3.660. Therefore, Genvec's PE Ratio for today is At Loss.


Genvec EV-to-FCF Historical Data

The historical data trend for Genvec's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec EV-to-FCF Chart

Genvec Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.19 -2.64 -10.25 -3.82 -0.02

Genvec Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genvec's EV-to-FCF

For the Biotechnology subindustry, Genvec's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genvec's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Genvec's EV-to-FCF falls into.



Genvec EV-to-FCF Calculation

Genvec's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=16.360/-7.098
=-2.30

Genvec's current Enterprise Value is $16.36 Mil.
Genvec's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genvec  (NAS:GNVC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Genvec's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=7.193/-3.660
=At Loss

Genvec's share price for today is $7.193.
Genvec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.660.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Genvec EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Genvec's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genvec (Genvec) Business Description

Traded in Other Exchanges
N/A
Address
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Executives
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman director 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum director GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky director, officer: President and CEO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins director, officer: President & CEO 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud director
Joshua Ruch director 4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 08-07-2009

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-11-2011

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 05-08-2009